JP2024523576A - 新規の選択的アンジオテンシンｉｉ化合物 - Google Patents

新規の選択的アンジオテンシンｉｉ化合物 Download PDF

Info

Publication number
JP2024523576A
JP2024523576A JP2023579654A JP2023579654A JP2024523576A JP 2024523576 A JP2024523576 A JP 2024523576A JP 2023579654 A JP2023579654 A JP 2023579654A JP 2023579654 A JP2023579654 A JP 2023579654A JP 2024523576 A JP2024523576 A JP 2024523576A
Authority
JP
Japan
Prior art keywords
methyl
sulfonamide
isobutyl
imidazol
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579654A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023281271A5 (https=
JP2024523576A5 (https=
Inventor
ナセル ピーターセン，ナディア
ハルベルグ，アンダース
ラーヘド，マッツ
フェックス，トーマス
オールソン，ベングト
Original Assignee
ヴィコール ファルマ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2109946.0A external-priority patent/GB202109946D0/en
Priority claimed from GBGB2202664.5A external-priority patent/GB202202664D0/en
Application filed by ヴィコール ファルマ アーベー filed Critical ヴィコール ファルマ アーベー
Publication of JP2024523576A publication Critical patent/JP2024523576A/ja
Publication of JPWO2023281271A5 publication Critical patent/JPWO2023281271A5/ja
Publication of JP2024523576A5 publication Critical patent/JP2024523576A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023579654A 2021-07-09 2022-07-08 新規の選択的アンジオテンシンｉｉ化合物 Pending JP2024523576A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2109946.0 2021-07-09
GBGB2109946.0A GB202109946D0 (en) 2021-07-09 2021-07-09 New compounds
GBGB2202664.5A GB202202664D0 (en) 2022-02-25 2022-02-25 New compounds
GB2202664.5 2022-02-25
PCT/GB2022/051760 WO2023281271A1 (en) 2021-07-09 2022-07-08 New selective angiotensin ii compounds

Publications (3)

Publication Number Publication Date
JP2024523576A true JP2024523576A (ja) 2024-06-28
JPWO2023281271A5 JPWO2023281271A5 (https=) 2025-07-15
JP2024523576A5 JP2024523576A5 (https=) 2025-07-15

Family

ID=82608432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579654A Pending JP2024523576A (ja) 2021-07-09 2022-07-08 新規の選択的アンジオテンシンｉｉ化合物

Country Status (11)

Country Link
US (2) US20240262813A1 (https=)
EP (1) EP4367110A1 (https=)
JP (1) JP2024523576A (https=)
KR (1) KR20240035402A (https=)
AU (1) AU2022306778A1 (https=)
CA (1) CA3222721A1 (https=)
CL (1) CL2024000066A1 (https=)
CO (1) CO2024000096A2 (https=)
IL (1) IL309605A (https=)
MX (1) MX2024000518A (https=)
WO (1) WO2023281271A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024000518A (es) 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500619A (ja) * 1996-02-20 2002-01-08 ブリストル―マイヤーズ・スクイブ・カンパニー 置換ビフェニルイソオキサゾールスルホンアミド
JP2002519380A (ja) * 1998-07-06 2002-07-02 ブリストル−マイヤーズ スクイブ カンパニー 二元アンギオテンシン／エンドセリン・レセプタ拮抗剤としてのビフェニルスルホンアミド化合物
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2009529005A (ja) * 2006-03-03 2009-08-13 トレント・ファーマシューティカルズ・リミテッド アンジオテンシン１受容体（ａｔ１）とエンドセリンａ（ｅｔａ）受容体に対する新規な二重作用受容体拮抗薬（ｄａｒａ）
US20120035232A1 (en) * 2010-06-11 2012-02-09 Vicore Pharma Ab Use of angiotensin ii agonists
WO2021053344A1 (en) * 2019-09-20 2021-03-25 Vicore Pharma Ab New compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
HUP9802034A3 (en) 1995-04-04 2000-04-28 Encysive Pharmaceuticals Inc H Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin and use of the compounds
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
KR20230004501A (ko) * 2020-03-19 2023-01-06 바이코어 파마 아베 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물
MX2024000518A (es) 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500619A (ja) * 1996-02-20 2002-01-08 ブリストル―マイヤーズ・スクイブ・カンパニー 置換ビフェニルイソオキサゾールスルホンアミド
JP2002519380A (ja) * 1998-07-06 2002-07-02 ブリストル−マイヤーズ スクイブ カンパニー 二元アンギオテンシン／エンドセリン・レセプタ拮抗剤としてのビフェニルスルホンアミド化合物
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2009529005A (ja) * 2006-03-03 2009-08-13 トレント・ファーマシューティカルズ・リミテッド アンジオテンシン１受容体（ａｔ１）とエンドセリンａ（ｅｔａ）受容体に対する新規な二重作用受容体拮抗薬（ｄａｒａ）
US20120035232A1 (en) * 2010-06-11 2012-02-09 Vicore Pharma Ab Use of angiotensin ii agonists
WO2021053344A1 (en) * 2019-09-20 2021-03-25 Vicore Pharma Ab New compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A．K.MAHALINGAM ET AL.: ""Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition"", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 18, no. 12, JPN6026009351, June 2010 (2010-06-01), pages 4570 - 4590, ISSN: 0005813316 *
CHARLOTTA WALLINDER ET AL.: ""Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 2, JPN6026009355, 16 December 2014 (2014-12-16), pages 178 - 182, ISSN: 0005813320 *
JOHAN WANNBERG ET AL.: ""A convenient transesterification method for synthesis of AT2 receptor ligands with improved stabil", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 28, no. 3, JPN6026009353, February 2018 (2018-02-01), pages 519 - 522, ISSN: 0005813318 *
XIONGYU WU ET AL.: ""Selective Angiotensin II AT2 Receptor Agonists: Arylbenzylimidazole Structure-Activity Relationshi", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 24, JPN6026009352, 9 November 2006 (2006-11-09), pages 7160 - 7168, ISSN: 0005813317 *
YIQIAN WAN ET AL.: ""Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 24, JPN6026009354, 15 October 2004 (2004-10-15), pages 5995 - 6008, ISSN: 0005813319 *

Also Published As

Publication number Publication date
IL309605A (en) 2024-02-01
US12441718B2 (en) 2025-10-14
CL2024000066A1 (es) 2024-06-28
AU2022306778A1 (en) 2024-01-18
KR20240035402A (ko) 2024-03-15
CO2024000096A2 (es) 2024-05-10
WO2023281271A1 (en) 2023-01-12
US20240262813A1 (en) 2024-08-08
CA3222721A1 (en) 2023-01-12
MX2024000518A (es) 2024-01-31
EP4367110A1 (en) 2024-05-15
US20250101010A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
JP7771049B2 (ja) 新化合物
CN115605265B (zh) 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物
US12441718B2 (en) Selective angiotensin II compounds
WO2022049372A1 (en) Novel compounds for use in the treatment of diseases associated with angiotensin ii
JP2024511452A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
GB2605148A (en) New compounds
EP4648850A1 (en) Selective angiotensin ii compounds
WO2022200785A1 (en) Selective angiotensin ii receptor ligands
JP2024511451A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
CN117916229A (zh) 新型选择性血管紧张素ii化合物
CN117222624A (zh) 选择性血管紧张素ii受体配体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310